SARM1 Inhibitors Market is segmented By Indication (Amyotrophic Lateral Sclerosis, Multiple Sclerosi...
Market Size in USD Mn
CAGR103.9%
Study Period | 2025-2032 |
Base Year of Estimation | 2024 |
CAGR | 103.9% |
Market Concentration | Medium |
Major Players | Disarm Therapeutics, Nura Bio, Washington University, Asha Therapeutics, UCB Pharma and Among Others |
The SARM1 Inhibitors Market is estimated to be valued at USD 10.2 Mn in 2025 and is expected to reach USD 1494.6 Mn by 2032, growing at a compound annual growth rate (CAGR) of 103.9% from 2025 to 2032.
The market is expected to witness positive growth over the forecast period. Factors such as high prevalence of neurological disorders such as spinal cord injuries and growing research & development for new drug molecules are expected to drive the demand. Promising clinical trial results of SARM1 inhibitors in treating various neurological conditions will further provide impetus to the growth. Additionally, rising geriatric population prone to neurological diseases complemented with increasing healthcare expenditures is anticipated to support the revenue generation.